This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Reinventing Brainlab
Herzlinger, Regina E.; Dessain, Vincent; Misztal, KarolCase HBS-313069-EStrategyThe management of Germany's Brainlab AG, a leading provider of software-driven oncology and surgery solutions, needs to evaluate strategic options for proceeding without an exclusive hardware partner in its most profitable business segment.Starting at €8.20
-
Morgan Asset Management
Groysberg, Boris; Healy, Paul M.; Abbott, Sarah L.Case HBS-411058-EAccounting and ControlIt is 2010 and Guillermo Araoz, the equity research director at Morgan Asset Management (MAM), is considering his research budget for the year. Due to recent declines in the equity markets and MAM's sale of its mutual funds business, MAM has seen a decline in its assets under management, and consequently, in its research budget. The case describes the investment process at MAM, including how stocks are selected and portfolios are constructed, and...Starting at €8.20
-
Sanofi Pasteur: The Dengue Vaccine Dilemma
Rangan, V. Kasturi; Bloom, David E.; Dessain, Vincent; Billaud, EmilieCase HBS-514074-EIn 2012, Sanofi Pasteur was racing to develop a vaccine against dengue, a mosquito-borne disease, and was evaluating this product in a Phase IIb trial conducted with school children in Thailand. But while the candidate vaccine met the high safety expectations and a good balanced immune answer, it had a proof of efficacy of only 30%, far below the 70% mark the company had targeted. Guillaume Leroy, vice president of the Dengue Company at Sanofi Pa...Starting at €8.20
-
Roche's Acquisition of Genentech
Baldwin, Carliss Y.; Becker, Bo; Dessain, VincentCase HBS-210040-EFinanceFranz Humer, CEO of the Roche Group, must decide whether to mount a hostile tender offer for the publicly-owned shares of Roche's biotechnology subsidiary, Genentech. The case provides opportunities to analyze Roche's strategy with respect to Genentech, tStarting at €8.20
-
The Novartis Malaria Initiative
Chu, Michael; Dessain, Vincent; Billaud, EmilieCase HBS-314103-EBusiness Ethics and Corporate Social ResponsibilityThe Novartis Malaria Initiative was designed, as a result of a precedent-setting agreement with the World Health Organization in 2001, to provide a breakthrough treatment for malaria-"at no profit"-for public health systems. What had begun as an exemplary act of corporate responsibility had succeeded beyond any expectations. In 2012, for the second year in a row, Novartis had manufactured and distributed over 100 million units of the anti-malaria...Starting at €8.20
-
-
Rajat Gupta, Teaching Note
Healy, Paul M.; Soltes, EugeneTeaching Note HBS-117068-ETeaching Note for HBS Case No.117-004, "Rajat Gupta"Starting at €0.00
-
Valuation at Novartis
Healy, Paul M.Case HBS-108041-EFinanceAn abstract is not available for this product.Starting at €8.20
-
Oddo Securities - ESG Integration
Serafeim, George; Healy, Paul M.; Sesia, AldoCase HBS-111085-EThe case describes the process of integrating environmental, social, and governance issues into valuation models and research analyst recommendations.Starting at €8.20
-
Eddie Bauer (B)
Healy, Paul M.; Katz, Sharon; Sesia, AldoCase HBS-110009-EAccounting and ControlIn February 2007, shareholders of Eddie Bauer, the specialty apparel retailer, were scheduled to vote on management's proposed sale of the company to two private equity firms. More than 50% of outstanding shares in Eddie Bauer needed to be voted in favor of the deal for it to be finalized. Shareholders needed to decide whether to vote for or against the proposed sale, which was fully endorsed by the board of Eddie Bauer.Starting at €5.74